KR20260053547A - 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물 - Google Patents

비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Info

Publication number
KR20260053547A
KR20260053547A KR1020267008720A KR20267008720A KR20260053547A KR 20260053547 A KR20260053547 A KR 20260053547A KR 1020267008720 A KR1020267008720 A KR 1020267008720A KR 20267008720 A KR20267008720 A KR 20267008720A KR 20260053547 A KR20260053547 A KR 20260053547A
Authority
KR
South Korea
Prior art keywords
bvd
braf
cancer
cells
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267008720A
Other languages
English (en)
Korean (ko)
Inventor
사우라브 사하
딘 웰쉬
개리 데크레스센조
제프리 제임스 로익스
Original Assignee
바이오메드 밸리 디스커버리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오메드 밸리 디스커버리즈, 인코포레이티드 filed Critical 바이오메드 밸리 디스커버리즈, 인코포레이티드
Publication of KR20260053547A publication Critical patent/KR20260053547A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
KR1020267008720A 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물 Pending KR20260053547A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361919551P 2013-12-20 2013-12-20
US15/161,137 2016-05-20
US15/161,137 US20160317519A1 (en) 2013-12-20 2016-05-20 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
KR1020237004648A KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
PCT/US2017/033843 WO2017201532A1 (en) 2013-12-20 2017-05-22 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004648A Division KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20260053547A true KR20260053547A (ko) 2026-04-21

Family

ID=53403903

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020267008720A Pending KR20260053547A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
KR1020237004648A Ceased KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
KR1020187037187A Ceased KR20190009804A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020237004648A Ceased KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
KR1020187037187A Ceased KR20190009804A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Country Status (15)

Country Link
US (6) US20160317519A1 (enExample)
EP (2) EP3458056B1 (enExample)
JP (4) JP7427212B2 (enExample)
KR (3) KR20260053547A (enExample)
CN (2) CN120501744A (enExample)
AU (3) AU2017267804B2 (enExample)
BR (1) BR112018073786A2 (enExample)
CL (1) CL2018003282A1 (enExample)
ES (1) ES3056393T3 (enExample)
IL (2) IL263108B (enExample)
MX (2) MX392121B (enExample)
RU (1) RU2018145048A (enExample)
SG (1) SG11201810287RA (enExample)
WO (2) WO2015095842A2 (enExample)
ZA (2) ZA201808480B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
WO2015095842A2 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112018012255A2 (pt) * 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
AU2017249229A1 (en) * 2016-04-15 2018-10-04 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017180817A1 (en) * 2016-04-15 2017-10-19 Musc Foundation For Research Development Treatment of septicemia and ards with erk inhibitors
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018213302A1 (en) * 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
ES2947411T3 (es) * 2017-10-26 2023-08-08 Xynomic Pharmaceuticals Inc Sales cristalinas de un campo inhibidor de quinasa B-RAF
WO2019199883A1 (en) * 2018-04-09 2019-10-17 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
CN110656172A (zh) * 2019-01-14 2020-01-07 南方医科大学珠江医院 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
KR102697384B1 (ko) * 2022-01-13 2024-08-22 팔라디바이오텍 주식회사 리셉터 티로신 키나제 저해제를 탐색하는 방법
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2026020045A1 (en) * 2024-07-17 2026-01-22 4M Therapeutics Inc. N-desmethyl ruboxistaurin as a rsk inhibitor for therapeutic use
WO2026030476A1 (en) * 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
ES2897422T3 (es) 2004-05-14 2022-03-01 Vertex Pharma Compuestos pirroles como inhibidores de proteínas cinasas ERK y composiciones farmacéuticas que contienen esos compuestos
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
JP2008545670A (ja) * 2005-05-27 2008-12-18 バイエル・ヘルスケア・アクチェンゲゼルシャフト 疾患を処置するためのジアリールウレア類を含む組合せ治療
TWI419974B (zh) 2008-10-27 2013-12-21 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
WO2014123612A1 (en) * 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Methods of treating melanoma
WO2014128235A1 (en) * 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
WO2015095833A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
BR112016014481B1 (pt) * 2013-12-20 2022-11-08 Biomed Valley Discoveries, Inc Uso de uma composição farmacêutica, método in vitro para efetuar a morte de células cancerosas, e kit
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
US10214743B2 (en) * 2014-03-04 2019-02-26 Hirofumi Yamamoto Colorectal cancer drug, and method for predicting prognosis of colorectal cancer patient
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
SG11201705924RA (en) * 2015-01-30 2017-08-30 Biomed Valley Discoveries Inc CRYSTALLINE FORMS OF C<sb>21</sb>H<sb>22</sb>CI<sb>2</sb>N<sb>4</sb>O<sb>2</sb>
US9670177B2 (en) * 2015-01-30 2017-06-06 Biomed Valley Discoveries, Inc. Crystalline C21H22Cl2N4O2 malonate

Also Published As

Publication number Publication date
WO2017201532A1 (en) 2017-11-23
US20160317519A1 (en) 2016-11-03
MX2018014231A (es) 2019-05-15
US11246859B2 (en) 2022-02-15
US20220117950A1 (en) 2022-04-21
EP3458056B1 (en) 2025-10-15
CN109475541A (zh) 2019-03-15
JP2019519519A (ja) 2019-07-11
CL2018003282A1 (es) 2019-10-18
JP2022034068A (ja) 2022-03-02
AU2025204585A1 (en) 2025-07-10
US20180104228A1 (en) 2018-04-19
AU2017267804A1 (en) 2019-01-17
JP2024133638A (ja) 2024-10-02
WO2015095842A3 (en) 2015-08-20
RU2018145048A (ru) 2020-06-22
US20260224546A1 (en) 2026-08-06
MX392121B (es) 2025-03-21
IL263108B (en) 2022-08-01
EP4653055A3 (en) 2026-03-18
ZA201808480B (en) 2022-04-28
WO2015095842A2 (en) 2015-06-25
IL294056A (en) 2022-08-01
BR112018073786A2 (pt) 2019-02-26
ZA202007734B (en) 2022-04-28
AU2023204587B2 (en) 2025-04-03
SG11201810287RA (en) 2018-12-28
KR20230025941A (ko) 2023-02-23
US20190201387A1 (en) 2019-07-04
EP4653055A2 (en) 2025-11-26
KR20190009804A (ko) 2019-01-29
EP3458056A4 (en) 2020-01-08
AU2017267804B2 (en) 2023-04-27
AU2023204587A1 (en) 2023-08-17
US12599593B2 (en) 2026-04-14
CA3024703A1 (en) 2017-11-23
CN120501744A (zh) 2025-08-19
ES3056393T3 (en) 2026-02-20
JP7427212B2 (ja) 2024-02-05
IL263108A (en) 2018-12-31
EP3458056A1 (en) 2019-03-27
US10881646B2 (en) 2021-01-05
MX2022005473A (es) 2022-06-02
US20210038587A1 (en) 2021-02-11
JP2026053745A (ja) 2026-03-25

Similar Documents

Publication Publication Date Title
AU2023204587B2 (en) Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers
RU2722784C2 (ru) Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
CN110799245B (zh) 用于治疗具有非典型braf突变的癌症的组合物和方法
Yen et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
AU2014368927B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
KR102958345B1 (ko) Hsd17b13 변종 및 이것의 용도
US20210189342A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
KR20210030947A (ko) Nlrp3 길항제를 사용한 tnf 억제제 저항성 대상체를 위한 치료 방법 또는 치료제의 선택 방법
KR101865426B1 (ko) Raf와 mek 억제제에 대한 내성을 부여하는 mek1 돌연변이
KR20140147797A (ko) 암 및 자가면역 질환의 치료 방법 및 조성물
WO2015066452A2 (en) Methods of treating pediatric cancers
WO2017106189A1 (en) Compositions and methods for treating ras/mapk mutant lung cancer
WO2020150480A1 (en) Methods for treatment of lung cancers
WO2019111998A1 (ja) 癌スフェロイドの製造方法および大腸癌患者の選択方法
US20210324478A1 (en) Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
WO2015049371A1 (en) Methods for predicting the responsiveness of a patient affected with chronic myeloid leukemia (cml) to a treatment with a tyrosine kinase inhibitor (tki)
RU2812706C2 (ru) Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf
HK40006110A (en) Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
HK40022785B (en) Compositions and methods for treating cancer with atypical braf mutations
HK40022785A (en) Compositions and methods for treating cancer with atypical braf mutations
RU2859009C2 (ru) Варианты hsd17b13 и их применения
WO2020115261A1 (en) Methods and compositions for treating melanoma

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)